Gastroesophageal reflux disease future or investigational therapies: Difference between revisions
(Created page with "__NOTOC__ {{Gastroesophageal reflux disease}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}}") |
|||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Future or Investigational Therapies== | |||
In 2000 , the U.S. [[Food and Drug Administration]] (FDA) approved two [[endoscopy|endoscopic]] devices to treat chronic heartburn. One system, Endocinch, puts stitches in the LES to create little pleats that help strengthen the muscle. Another, the [[stretta procedure|Stretta Procedure]], uses electrodes to apply radio frequency energy to the LES. The long term outcomes of both procedures compared to a Nissen fundoplication are still being determined. | |||
Subsequently the NDO Surgical Plicator was FDA cleared for the endoscopic GERD treatment. The Plicator creates a plication, or fold, of tissue near the gastroesophageal junction, and fixates the plication with a suture-based implant. The Plicator is currently marketed by NDO Surgical, Inc. [http://www.ndosurgical.com]. | |||
Another treatment that involved injection of a solution during endoscopy into the lower esophageal wall was available for about one year ending in late 2005. It was marketed under the name Enteryx. It was removed from the market due to several reports of complications from misplaced injections. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 23:04, 30 August 2012
|
Gastroesophageal reflux disease Microchapters |
|
Differentiating Gastroesophageal Reflux Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastroesophageal reflux disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Gastroesophageal reflux disease future or investigational therapies |
|
FDA on Gastroesophageal reflux disease future or investigational therapies |
|
CDC on Gastroesophageal reflux disease future or investigational therapies |
|
Gastroesophageal reflux disease future or investigational therapies in the news |
|
Blogs on Gastroesophageal reflux disease future or investigational therapies |
|
Directions to Hospitals Treating Gastroesophageal reflux disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
In 2000 , the U.S. Food and Drug Administration (FDA) approved two endoscopic devices to treat chronic heartburn. One system, Endocinch, puts stitches in the LES to create little pleats that help strengthen the muscle. Another, the Stretta Procedure, uses electrodes to apply radio frequency energy to the LES. The long term outcomes of both procedures compared to a Nissen fundoplication are still being determined.
Subsequently the NDO Surgical Plicator was FDA cleared for the endoscopic GERD treatment. The Plicator creates a plication, or fold, of tissue near the gastroesophageal junction, and fixates the plication with a suture-based implant. The Plicator is currently marketed by NDO Surgical, Inc. [2].
Another treatment that involved injection of a solution during endoscopy into the lower esophageal wall was available for about one year ending in late 2005. It was marketed under the name Enteryx. It was removed from the market due to several reports of complications from misplaced injections.